Routine hydroxy-chloroquine blood concentration measurement in systemic lupus erythematosus reaches adulthood

Journal of Rheumatology

Volumn 42, Issue 11, 2015, Pages 1997-1999

  Costedoat Chalumeau, Nathalie ^a   Le Guern, Véronique ^a   Piette, Jean Charles ^a  

^a Université Paris Descartes Sorbonne Paris Cité ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE;

ADULTHOOD; DISEASE ACTIVITY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; EDITORIAL; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MEDICATION COMPLIANCE; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PHARMACODYNAMICS; PIGMENT DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SKIN TOXICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; STATISTICS AND NUMERICAL DATA;

FEMALE; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEDICATION ADHERENCE;

EID: 84946592703     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.151094     Document Type: Editorial

References (17)

1. van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958-67.
2. Tett S, Day R, Cutler D. Hydroxychloroquine relative bioavailability: within subject reproducibility. Br J Clin Pharmacol 1996;41:244-6.
3. Tett SE, Cutler DJ, Beck C, Day RO. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis-a prospective, dose ranging study. J Rheumatol 2000;27:1656-60.
4. Tett SE, Day RO, Cutler DJ. Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis - a cross sectional study. J Rheumatol 1993;20:1874-9.
5. Munster T, Gibbs JP, Shen D, Baethge BA, Botstein GR, Caldwell J et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:1460-9.
6. Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:3284-90.
7. Frances C, Cosnes A, Duhaut P, Zahr N, Soutou B, Ingen-Housz-Oro S, et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 2012;148:479-84.
8. Costedoat-Chalumeau N, Galicier L, Aumaitre O, Frances C, Le Guern V, Liote F, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 2013;72:1786-92.
9. Jallouli M, Galicier L, Zahr N, Aumaitre O, Frances C, Le Guern V, et al. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol 2015;67:2176-84.
10. Ting TV, Kudalkar D, Nelson S, Cortina S, Pendl J, Budhani S, et al. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol 2012;39:174-9.
11. Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine blood levels in SLE: Clarifying dosing controversies and improving adherence. J Rheumatol 2015;42:2092-7.
12. Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, Le Guern V, Leroux G, Marra D, et al. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 2013;27:329-40.
13. Lee JY, Vinayagamoorthy N, Han K, Kwok SK, Ju JH, Park KS, et al. Polymorphisms of cytochrome P450 2D6 are associated with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol 2015 Aug 28 (E-pub ahead of print).
14. Jallouli M, Frances C, Piette JC, Huong DL, Moguelet P, Factor C, et al. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. JAMA Dermatol 2013;149:935-40.
15. Costedoat-Chalumeau N, Dunogue B, Leroux G, Morel N, Jallouli M, Le Guern V, et al. A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol 2015 Feb 12 (E-pub ahead of print).
16. Croyle L, Morand EF. Optimizing the use of existing therapies in lupus. Int J Rheum Dis 2015;18:129-37.
17. Alexander S, Chusney G, Chusney VD, Lee J, Cairns T, Lightstone L. The achilles heel of lupus nephritis treatment-identifying non adherence using hydroxychloroquine blood levels (abstract PO06). J Am Soc Nephrol 2013;24:790A.